Product Description
Lurasidone is a medication used in the treatment of schizophrenia and bipolar depression. It is in the benzisothiazole class of medications. (Sourced from: https://www.ncbi.nlm.nih.gov/books/NBK541057/)
Mechanisms of Action: D2 Antagonist, 5-HT2A Antagonist, 5-HT7 Antagonist, ADRA2A Antagonist, ADRA2C Antagonist, 5-HT1A Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Approved
Approved Countries: Argentina | Australia | Austria | Bangladesh | Belgium | Brazil | Canada | China | Colombia | Croatia | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | Germany | Greece | Hong Kong | Hungary | Iceland | India | Ireland | Italy | Japan | Jordan | Latvia | Lebanon | Lithuania | Malaysia | Netherlands | Norway | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Singapore | Slovakia | Slovenia | Spain | Sweden | Switzerland | Taiwan | Turkey | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela
Approved Indications: None
Known Adverse Events: None
Company: Dainippon Sumitomo Pharma America
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Japan
Active Clinical Trial Count: 1
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Schizophrenia
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
jRCT2011210024 |
jRCT2011210024 | P3 |
Recruiting |
Schizophrenia |
2025-01-31 |